Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Lung Cancer

Free Subscription Articles published in Oncol Rep Retrieve available abstracts of 53 articles: HTML format

Single Articles

June 2026
1. ZHOU Y, Ma J, Zhang J, He L, et al
   [Expression of Concern] Pifithrin?mu is efficacious against non?small cell lung cancer via inhibition of heat shock protein 70.
   Oncol Rep. 2026;55:118.
   PubMed     Abstract available
   
   
   May 2026
2. HU P, Li A
   ACSBG1?driven lipid reprogramming unveiled: A fatty acid metabolism?associated prognostic model for lung adenocarcinoma.
   Oncol Rep. 2026;55:82.
   PubMed     Abstract available
   
   
   April 2026
3. KOBAYASHI M, Konno C, Shimizu A, Kobayashi M, et al
   Tumor?associated glucocorticoid inhibition by mifepristone reduces polymorphonuclear myeloid?derived suppressor cells and promotes antitumor immunity in triple?negative breast cancer?bearing mice.
   Oncol Rep. 2026;55:60.
   PubMed     Abstract available
   
   
   
4. JIN S, Zhang D, Liao Z, Yu L, et al
   TRIM46 deficiency?induced DNA damage enhances the sensitivity of cisplatin in non?small cell lung cancer by regulating the Akt signaling pathway.
   Oncol Rep. 2026;55:58.
   PubMed     Abstract available
   
   
   
5. GUO M, Li H, Zhao Z, Wang Y, et al
   Suppressive role of SCN4B in the epithelial?mesenchymal transition of lung adenocarcinoma.
   Oncol Rep. 2026;55:68.
   PubMed     Abstract available
   
   
   March 2026
6. SHARMA U, Song J, Kandu H, Zhu Y, et al
   Advances in targeting KRAS mutations: A promising approach for the treatment of non?small cell lung cancer (Review).
   Oncol Rep. 2026;55:39.
   PubMed     Abstract available
   
   
   
7. MA H, Li L, Jiao C, Cheng Y, et al
   

   Immunotherapy after EGFR?TKI treatment in advanced non?small cell lung cancer: Current status and future perspectives (Review)

   .
   Oncol Rep. 2026;55:44.
   PubMed     Abstract available
   
   
   
8. JIANG J, Dong G, Zhang Z, Lei X, et al
   Recapitulating lung cancer metastasis in vitro: Advances in organoid models and challenges in clinical translation (Review).
   Oncol Rep. 2026;55:49.
   PubMed     Abstract available
   
   
   February 2026
9. JIN L, Wei L, Hua J, Zhang R, et al
   Inhibition of primary ciliogenesis enhances efficacy of EGFR?TKIs against non?small cell lung cancer cells.
   Oncol Rep. 2026;55:30.
   PubMed     Abstract available
   
   
   January 2026
10. WANG K, Li Y, Guo Z, Song L, et al
    Role of the SOX family in non?small cell lung cancer: Molecular mechanisms and therapeutic implications (Review).
    Oncol Rep. 2026;55:19.
    PubMed     Abstract available
    
    
    
11. YIN Y, Tang L, Shi L
    [Corrigendum] Src homology phosphotyrosyl phosphatase 2 mediates cisplatin?related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.
    Oncol Rep. 2026;55:21.
    PubMed     Abstract available
    
    
    December 2025
12. ZHENG WW, Ding JX, Liang YX, Ye L, et al
    Hydroxypropyl?beta?cyclodextrin/thymoquinone inclusion complex inhibits non?small cell lung cancer progression through NF?kappaB?mediated ferroptosis.
    Oncol Rep. 2025;54:157.
    PubMed     Abstract available
    
    
    
13. ZHAO C, Xu Y, Zhang Y, Tan W, et al
    [Expression of Concern] Downregulation of miR?145 contributes to lung adenocarcinoma cell growth to form brain metastases.
    Oncol Rep. 2025;54:158.
    PubMed     Abstract available
    
    
    November 2025
14. LEI Y, Guo W, Chen B, Chen L, et al
    [Retracted] Tumor?released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non?small cell lung cancer.
    Oncol Rep. 2025;54:140.
    PubMed     Abstract available
    
    
    
15. WU A, Ni Y, Zhou Y, Shi J, et al
    Emerging dual role of ferroptosis in lung cancer (Review).
    Oncol Rep. 2025;54:141.
    PubMed     Abstract available
    
    
    
16. TANG C, Hahm E, Bae S, Kang JS, et al
    [Expression of Concern] Src homology phosphotyrosyl phosphatase 2 mediates cisplatin?related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.
    Oncol Rep. 2025;54:146.
    PubMed     Abstract available
    
    
    
17. WU X, Qu C, Ouyang Y, Yang L, et al
    T cell exhaustion?related gene CD79B predicts prognosis, inhibits malignant progression and promotes tumor?associated macrophage M1?like polarization in lung adenocarcinoma.
    Oncol Rep. 2025;54:144.
    PubMed     Abstract available
    
    
    
18. LV Q, Xu J, Hu N, Zhao Y, et al
    Lactylation modification in lung cancer: A review of current research and future directions (Review).
    Oncol Rep. 2025;54:148.
    PubMed     Abstract available
    
    
    October 2025
19. LIN Z, Chen Q, Chen Z, Peng T, et al
    Advances in the chemo?preventive effects and mechanisms of ursolic acid against lung cancer (Review).
    Oncol Rep. 2025;54:126.
    PubMed     Abstract available
    
    
    
20. FUJIYOSHI K, Sugihara R, Miyamoto N, Watanabe Y, et al
    Comprehensive genetic profiling using tissue and blood in locally advanced tumors.
    Oncol Rep. 2025;54:134.
    PubMed     Abstract available
    
    
    September 2025
21. DU J, Gong X, Huang R, Zheng B, et al
    Harnessing CRISPR/Cas9 to overcome targeted therapy resistance in non?small cell lung cancer: Advances and challenges (Review).
    Oncol Rep. 2025;54:111.
    PubMed     Abstract available
    
    
    
22. KIM MS, Kim MS
    TRPML3?mediated lysosomal Ca(2+) release enhances drug sequestration and biogenesis, promoting osimertinib resistance in non?small cell lung cancer.
    Oncol Rep. 2025;54:113.
    PubMed     Abstract available
    
    
    August 2025
23. ZINNAH KMA, Park SY
    [Corrigendum] Sensitizing TRAIL?resistant A549 lung cancer cells and enhancing TRAIL?induced apoptosis with the antidepressant amitriptyline.
    Oncol Rep. 2025;54:87.
    PubMed     Abstract available
    
    
    July 2025
24. YAN Y, Kong X, Jin X, Bu J, et al
    RNA?binding protein MBNL1 regulates tumor growth, chemosensitivity and antitumor immunity in lung adenocarcinoma by controlling the expression of tumor suppressor RNF125.
    Oncol Rep. 2025;54:74.
    PubMed     Abstract available
    
    
    June 2025
25. YUAN Q, Li X, Chen X, Xiao J, et al
    7?Difluoromethoxyl?5,4'?di?n?octylygenistein targets the STAT3 pathway by upregulating microRNA?152?3p expression to inhibit self?renewal and tumor growth in non?small cell lung carcinoma.
    Oncol Rep. 2025;53:66.
    PubMed     Abstract available
    
    
    May 2025
26. HU Y, Liu X, Yuan Z, He J, et al
    Induction of necroptosis in lung adenocarcinoma by miR?10b?5p through modulation of the PKP3/RIPK3/MLKL cascade.
    Oncol Rep. 2025;53:56.
    PubMed     Abstract available
    
    
    
27. LIN GB, Chen WT, Kuo YY, Liu HH, et al
    Thermal cycling?hyperthermia sensitizes non?small cell lung cancer A549 cells to EGFR tyrosine kinase inhibitor erlotinib.
    Oncol Rep. 2025;53:58.
    PubMed     Abstract available
    
    
    
28. ZHANG J, Qi S, Du Y, Dai H, et al
    Effect of quercetin on inhibiting gefitinib?activated non?small cell lung cancer?induced cell pyroptosis in cardiomyocytes via modulating mitochondrial autophagy mediated by the SHP2/ROS/AMPK/XBP?1/DJ?1 signaling pathway.
    Oncol Rep. 2025;53:57.
    PubMed     Abstract available
    
    
    April 2025
29. ZHANG L, Wang S, Wang L
    Pan?cancer analysis of oncogene SFXN1 to identify its prognostic and immunological roles in lung adenocarcinoma.
    Oncol Rep. 2025;53:50.
    PubMed     Abstract available
    
    
    February 2025
30. PENG Y, Li D, Wampfler JA, Luo YH, et al
    Targeted therapy?associated cardiotoxicity in patients with stage?IV lung cancer with or without cardiac comorbidities.
    Oncol Rep. 2025;53:25.
    PubMed     Abstract available
    
    
    
31. ZHOU S, Sun J, Zhu W, Yang Z, et al
    Hypoxia studies in non?small cell lung cancer: Pathogenesis and clinical implications (Review).
    Oncol Rep. 2025;53:29.
    PubMed     Abstract available
    
    
    January 2025
32. MUTO S, Homma MK, Kiko Y, Ozaki Y, et al
    Nucleolar casein kinase 2 alpha as a prognostic factor in patients with surgically resected early?stage lung adenocarcinoma.
    Oncol Rep. 2025;53:4.
    PubMed     Abstract available
    
    
    
33. WANG M, Chen X, Fu G, Ge M, et al
    [Retracted] Glutathione peroxidase 2 overexpression promotes malignant progression and cisplatin resistance of KRAS?mutated lung cancer cells.
    Oncol Rep. 2025;53:1.
    PubMed     Abstract available
    
    
    December 2024
34. WEI Q, Lin J, Lin Z, Yu N, et al
    GOLPH3 inhibition overcomes cisplatin resistance by restoring the glutathione/reactive oxygen species balance in the A549 non?small cell lung cancer cell line.
    Oncol Rep. 2024;52:170.
    PubMed     Abstract available
    
    
    
35. HU X, Zhang S, Zhang X, Liu H, et al
    HOXD1 inhibits lung adenocarcinoma progression and is regulated by DNA methylation.
    Oncol Rep. 2024;52:173.
    PubMed     Abstract available
    
    
    November 2024
36. GUI H, Nie Y, Yuan H, Jing Q, et al
    The combination of a PTP1B inhibitor, TNFR2 blocker, and PD?1 antibody suppresses the progression of non?small cell lung cancer tumors by enhancing immunocompetence.
    Oncol Rep. 2024;52:149.
    PubMed     Abstract available
    
    
    
37. KANAYAMA M, Yoneda K, Kuwata T, Mori M, et al
    Enhanced capture system for mesenchymal?type circulating tumor cells using a polymeric microfluidic device 'CTC?Chip' incorporating cell?surface vimentin.
    Oncol Rep. 2024;52:156.
    PubMed     Abstract available
    
    
    
38. GEORGAKOPOULOU VE, Lempesis IG, Trakas N, Sklapani P, et al
    Lung cancer and obesity: A contentious relationship (Review).
    Oncol Rep. 2024;52:158.
    PubMed     Abstract available
    
    
    October 2024
39. ZHOU M, Wei L, Lu R
    Emerging role of sirtuins in non?small cell lung cancer (Review).
    Oncol Rep. 2024;52:127.
    PubMed     Abstract available
    
    
    
40. WEI W, Zhao X, Zhu J, Zhang L, et al
    [Retracted] lncRNA?u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling.
    Oncol Rep. 2024;52:126.
    PubMed     Abstract available
    
    
    
41. MUNKHJARGAL B, Kondo K, Soejima S, Tegshee B, et al
    DNA methylation and mRNA expression of ZNF577 as biomarkers for the detection and prognosis of lung adenocarcinoma.
    Oncol Rep. 2024;52:131.
    PubMed     Abstract available
    
    
    August 2024
42. LI S, Wang H, Ma R, Wang L, et al
    [Retracted] Schisandrin B inhibits epithelial?mesenchymal transition and stemness of large?cell lung cancer cells and tumorigenesis in xenografts via inhibiting the NF?kappaB and p38 MAPK signaling pathways.
    Oncol Rep. 2024;52:102.
    PubMed     Abstract available
    
    
    July 2024
43. CHENG SH, Tu KY, Lee HH
    The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment (Review).
    Oncol Rep. 2024;52:96.
    PubMed     Abstract available
    
    
    June 2024
44. GAO Y, Zhang G, Liu J, Li H, et al
    [Retracted] Tissue?specific transplantation antigen P35B functions as an oncogene and is regulated by microRNA?125a?5p in lung cancer.
    Oncol Rep. 2024;51:76.
    PubMed     Abstract available
    
    
    February 2024
45. ZHANG F, Qi Y, Li J, Liu B, et al
    Activin A induces apoptosis of human lung adenocarcinoma A549 cells through endoplasmic reticulum stress pathway.
    Oncol Rep. 2024;51:29.
    PubMed     Abstract available
    
    
    
46. LU X, Ma S, Li Y, Pan Y, et al
    Identification of ITGB4 as a novel tumor promoting gene in lung adenocarcinoma (LUAD).
    Oncol Rep. 2024;51:30.
    PubMed     Abstract available
    
    
    
47. LOU H, Wu Z, Wei G
    CDC6 may serve as an indicator of lung adenocarcinoma prognosis and progression based on TCGA and GEO data mining and experimental analyses.
    Oncol Rep. 2024;51:35.
    PubMed     Abstract available
    
    
    January 2024
48. CHENG Z, Cui H, Wang Y, Yang J, et al
    The advance of the third?generation EGFR?TKI in the treatment of non?small cell lung cancer (Review).
    Oncol Rep. 2024;51:16.
    PubMed     Abstract available
    
    
    December 2023
49. LIU J, Zhang F, Wang J, Wang Y, et al
    MicroRNA?mediated regulation in lung adenocarcinoma: Signaling pathways and potential therapeutic implications (Review).
    Oncol Rep. 2023;50:211.
    PubMed     Abstract available
    
    
    November 2023
50. CHEN Z, Li P, Shen L, Jiang X, et al
    Heat shock protein B7 (HSPB7) inhibits lung adenocarcinoma progression by inhibiting glycolysis.
    Oncol Rep. 2023;50:196.
    PubMed     Abstract available
    
    
    
51. WU Z, Liu S, Pang G, Jiang H, et al
    RNA?binding protein quaking 5 inhibits the progression of non?small cell lung cancer by upregulating netrin?4 expression.
    Oncol Rep. 2023;50:204.
    PubMed     Abstract available
    
    
    
52. TIAN C, Li J, Ren L, Peng R, et al
    [Retracted] MicroRNA?381 serves as a prognostic factor and inhibits migration and invasion in non?small cell lung cancer by targeting LRH?1.
    Oncol Rep. 2023;50:203.
    PubMed     Abstract available
    
    
    
53. ZHANG J, Darman L, Hassan MS, Von Holzen U, et al
    Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
    Oncol Rep. 2023;50:206.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum